Inhalable imatinib formulations, manufacture, and uses thereof

Abstract

The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.

What is claimed is: 
     
         1 . An inhalable formulation consisting of at least about 50% imatinib or a salt thereof. 
     
     
         2 . The inhalable formulation of  claim 1 , wherein the inhalable formulation further comprises one or more carrier agents. 
     
     
         3 . The inhalable formulation of  claim 2 , wherein the imatinib or salt thereof makes up about 50% of the formulation and the one or more carrier agents makes up about 50% of the formulation. 
     
     
         4 . The inhalable formulation of  claim 2 , wherein the one or more carrier agents comprise lactose. 
     
     
         5 . The inhalable formulation of  claim 1 , wherein the inhalable formulation is a dry powder. 
     
     
         6 . The inhalable formulation of  claim 1 , wherein the imatinib or salt thereof is present in a therapeutically effective amount to treat a condition of the pulmonary cardiovascular system. 
     
     
         7 . The inhalable formulation of  claim 6 , wherein the condition of the pulmonary cardiovascular system is pulmonary arterial hypertension (PAH). 
     
     
         8 . The inhalable formulation of  claim 1 , wherein greater than 80% of the imatinib or salt thereof in the inhalable formulation is present in a single crystal form. 
     
     
         9 . The inhalable formulation of  claim 8 , wherein the single crystal form is type A. 
     
     
         10 . The inhalable formulation of  claim 1 , wherein the salt is at least one selected from the group consisting of glycolate, malate, tartrate, malonate, isethionate, and citrate. 
     
     
         11 . A method of treating a condition of the pulmonary cardiovascular system, the method comprising providing to a subject an inhalable formulation consisting of at least about 50% imatinib or a salt thereof. 
     
     
         12 . The method of  claim 11 , wherein the inhalable formulation further comprises one or more carrier agents. 
     
     
         13 . The method of  claim 11 , wherein the imatinib or salt thereof makes up about 50% of the formulation and the one or more carrier agents makes up about 50% of the formulation. 
     
     
         14 . The method of  claim 13 , wherein the one or more carrier agents comprise lactose. 
     
     
         15 . The method of  claim 11 , wherein the inhalable formulation is a dry powder. 
     
     
         16 . The method of  claim 11 , wherein the subject is a human. 
     
     
         17 . The method of  claim 11 , wherein the condition of the pulmonary cardiovascular system is pulmonary arterial hypertension (PAH). 
     
     
         18 . The method of  claim 11 , wherein the salt is at least one selected from the group consisting of glycolate, malate, tartrate, malonate, isethionate, and citrate. 
     
     
         19 . The method of  claim 11 , wherein greater than 80% of the imatinib or salt thereof in the inhalable formulation is present in a single crystal form. 
     
     
         20 . The method of  claim 19 , wherein the single crystal form is type A.